Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: September 26, 2022

Patent: 5,631,322

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 5,631,322
Title: Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
Abstract:Polymers of the monomer N-acryloylmorpholine having a single reactive moiety at one end of the polymer chain have the following structure: ##STR1## wherein --Z--X--Y is a polymer capping moiety, such as mercaptan, X represents a saturated residue of a linear or branched aliphatic series of the general structure --C.sub.r H.sub.2r -- in which r is an integer from 1 to about 12, Y is a reactive moiety and typically will be one of the reactive moieties commonly known in PEG chemistry, such as an --OH, --COOH, or --NH.sub.2 group, Z is a moiety that readily reacts to cap a polymer free radical, and n is an integer from about 6 to 280, which yields a number average molecular weight (\"M.sub.n \") of from about 1,000 to 40,000. The monofunctional polymer is a suitable alternative to monofunctional PEG for modification of substances having biological and biotechnical applications.
Inventor(s): Veronese; Francesco M. (Padua, IT), Schiavon; Oddone (Padua, IT), Caliceti; Paolo (Padua, IT), Sartore; Luciana (Marano Vic., IT), Ranucci; Elisabetta (Brescia, IT), Ferruti; Paolo (Milan, IT)
Assignee: Consiglio Nazionale delle Ricerche (IT)
Application Number:08/475,177
Patent Claims:see list of patent claims

Details for Patent 5,631,322

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 See Plans and Pricing 2014-05-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.